Wu X - Search Results

1

REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.

Sun S, Hu Z, Huang S, Ye X, Wang J, Chang J, Wu X, Wang Q, Zhang L, Hu X, Yu H. Sun S, et al. Among authors: wu x. J Cancer Res Clin Oncol. 2019 Sep;145(9):2273-2283. doi: 10.1007/s00432-019-02988-y. Epub 2019 Aug 19. J Cancer Res Clin Oncol. 2019. PMID: 31428934

2

A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.

Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J, Guo Y, Lou D, Yu D, Li J. Chang J, et al. Among authors: wu x. Cancer Biol Ther. 2009 Apr;8(8):676-82. doi: 10.4161/cbt.8.8.7913. Epub 2009 Apr 22. Cancer Biol Ther. 2009. PMID: 19242097 Free article. Clinical Trial.

3

Prognostic factors in primary gastric non-Hodgkin's lymphoma--a single-center retrospective analysis of 103 cases from China.

Zhang J, Hu X, Liu X, Wu X, Sun S, Zhang Q, Zhao X, Ren H, Hong X. Zhang J, et al. Among authors: wu x. Hepatogastroenterology. 2010 Jul-Aug;57(101):989-96. Hepatogastroenterology. 2010. PMID: 21033265

4

Lack of association between methylenetetrahydrofolate reductase gene A1298C polymorphism and breast cancer susceptibility.

Qiu LX, Zhang J, Li WH, Zhang QL, Yu H, Wang BY, Wang LP, Wang JL, Wang HJ, Liu XJ, Luo ZG, Wu XH. Qiu LX, et al. Mol Biol Rep. 2011 Apr;38(4):2295-9. doi: 10.1007/s11033-010-0361-2. Epub 2010 Nov 5. Mol Biol Rep. 2011. PMID: 21052845

5

Continuous infusion of 5-FU with split-dose cisplatin: an effective treatment for advanced squamous-cell carcinoma of the head and neck.

Luo Z, Chang J, Guo Y, Yu H, Lu F, Wu X, Li J. Luo Z, et al. Among authors: wu x. Clin Invest Med. 2011 Feb 1;34(1):E8-13. doi: 10.25011/cim.v34i1.14907. Clin Invest Med. 2011. PMID: 21291636 Clinical Trial.

6

miR-196a2 C allele is a low-penetrant risk factor for cancer development.

Qiu LX, Wang Y, Xia ZG, Xi B, Mao C, Wang JL, Wang BY, Lv FF, Wu XH, Hu LQ. Qiu LX, et al. Cytokine. 2011 Dec;56(3):589-92. doi: 10.1016/j.cyto.2011.08.019. Epub 2011 Sep 9. Cytokine. 2011. PMID: 21907588

7

A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.

Wang J, Chang J, Yu H, Wu X, Wang H, Li W, Ji D, Peng W. Wang J, et al. Among authors: wu x. Cancer Chemother Pharmacol. 2013 Apr;71(4):905-11. doi: 10.1007/s00280-013-2081-5. Epub 2013 Feb 1. Cancer Chemother Pharmacol. 2013. PMID: 23370661 Clinical Trial.

8

A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.

Yu H, Zhang J, Wu X, Luo Z, Wang H, Sun S, Peng W, Qiao J, Feng Y, Wang J, Chang J. Yu H, et al. Among authors: wu x. Cancer Biol Ther. 2014 Jul;15(7):832-9. doi: 10.4161/cbt.28874. Epub 2014 Apr 22. Cancer Biol Ther. 2014. PMID: 24755888 Free PMC article. Clinical Trial.

9

A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.

Xing K, Zhou X, Zhao X, Sun S, Luo Z, Wang H, Yu H, Wang J, Chang J, Wu X, Hu A. Xing K, et al. Among authors: wu x. Med Oncol. 2014 Jul;31(7):36. doi: 10.1007/s12032-014-0036-2. Epub 2014 Jun 8. Med Oncol. 2014. PMID: 24908064

10

Decreased expression of RPS15A suppresses proliferation of lung cancer cells.

Zhao X, Shen L, Feng Y, Yu H, Wu X, Chang J, Shen X, Qiao J, Wang J. Zhao X, et al. Among authors: wu x. Tumour Biol. 2015 Sep;36(9):6733-40. doi: 10.1007/s13277-015-3371-9. Epub 2015 Apr 3. Tumour Biol. 2015. PMID: 25833696

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58,230 results

Search Page

Filters